FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
FibroBiologics (Nasdaq: FBLG) has announced the opening of a new laboratory facility in Houston, Texas, marking a significant expansion of its research capabilities in fibroblast-based therapeutics. The new facility spans over 10,000 square feet of lab and office space, designed to accelerate the development of treatments for chronic diseases.
The expansion will enable the company to:
- Increase the pace of discovery for potential therapeutics
- Enhance development of treatment candidates
- Potentially bring GMP manufacturing in-house for drug product candidates
- Hire additional researchers
The company, which holds 240+ patents issued and pending, aims to streamline its supply chain and reduce reliance on external partners through this expansion. The facility will allow for broader pipeline exploration and more effective collaboration in developing fibroblast-based technology.
FibroBiologics (Nasdaq: FBLG) ha annunciato l'apertura di una nuova struttura di laboratorio a Houston, Texas, segnando un'importante espansione delle sue capacità di ricerca nelle terapie basate sui fibroblasti. La nuova struttura si estende su oltre 10.000 piedi quadrati di spazio per laboratori e uffici, progettata per accelerare lo sviluppo di trattamenti per malattie croniche.
L'espansione permetterà all'azienda di:
- Aumentare il ritmo delle scoperte per potenziali terapie
- Migliorare lo sviluppo dei candidati per i trattamenti
- Potenzialmente portare la produzione GMP internamente per i candidati ai prodotti farmaceutici
- Assumere ulteriori ricercatori
L'azienda, che detiene oltre 240 brevetti emessi e in attesa, mira a semplificare la propria catena di approvvigionamento e ridurre la dipendenza da partner esterni attraverso questa espansione. La struttura permetterà un'esplorazione più ampia del pipeline e una collaborazione più efficace nello sviluppo della tecnologia basata sui fibroblasti.
FibroBiologics (Nasdaq: FBLG) ha anunciado la apertura de una nueva instalación de laboratorio en Houston, Texas, marcando una expansión significativa de sus capacidades de investigación en terapias basadas en fibroblastos. La nueva instalación abarca más de 10,000 pies cuadrados de espacio de laboratorio y oficinas, diseñada para acelerar el desarrollo de tratamientos para enfermedades crónicas.
La expansión permitirá a la empresa:
- Aumentar el ritmo de descubrimiento de terapias potenciales
- Mejorar el desarrollo de candidatos a tratamientos
- Potencialmente llevar la fabricación GMP internamente para candidatos a productos farmacéuticos
- Contratar a investigadores adicionales
La empresa, que posee más de 240 patentes emitidas y pendientes, tiene como objetivo optimizar su cadena de suministro y reducir la dependencia de socios externos a través de esta expansión. La instalación permitirá una exploración más amplia de su pipeline y una colaboración más efectiva en el desarrollo de tecnología basada en fibroblastos.
FibroBiologics (Nasdaq: FBLG)는 텍사스 휴스턴에 새로운 실험실 시설을 개설했다고 발표하며, 이는 섬유아세포 기반 치료법 연구 능력을 크게 확장하는 것을 의미합니다. 새로운 시설은 10,000 제곱피트 이상의 실험실 및 사무 공간을 차지하고 있으며, 만성 질환 치료 개발을 가속화하도록 설계되었습니다.
이번 확장은 회사가 다음을 가능하게 합니다:
- 잠재적 치료법 발견의 속도 증가
- 치료 후보 개발 향상
- 약물 제품 후보에 대한 GMP 제조를 내부화할 가능성
- 추가 연구원 채용
240건 이상의 특허를 보유한 이 회사는 이번 확장을 통해 공급망을 간소화하고 외부 파트너에 대한 의존도를 줄이는 것을 목표로 하고 있습니다. 이 시설은 더 넓은 파이프라인 탐색과 섬유아세포 기반 기술 개발에 있어 보다 효과적인 협업을 가능하게 할 것입니다.
FibroBiologics (Nasdaq: FBLG) a annoncé l'ouverture d'une nouvelle installation de laboratoire à Houston, Texas, marquant une expansion significative de ses capacités de recherche dans les thérapies basées sur les fibroblastes. La nouvelle installation s'étend sur plus de 10 000 pieds carrés d'espace de laboratoire et de bureau, conçue pour accélérer le développement de traitements pour les maladies chroniques.
Cette expansion permettra à l'entreprise de:
- Augmenter le rythme de découverte de thérapies potentielles
- Améliorer le développement des candidats traitements
- Potentiellement internaliser la fabrication GMP pour les candidats aux produits pharmaceutiques
- Embaucher des chercheurs supplémentaires
L'entreprise, qui détient plus de 240 brevets délivrés et en attente, vise à rationaliser sa chaîne d'approvisionnement et à réduire sa dépendance à l'égard de partenaires externes grâce à cette expansion. L'installation permettra une exploration plus large du pipeline et une collaboration plus efficace dans le développement de technologies basées sur les fibroblastes.
FibroBiologics (Nasdaq: FBLG) hat die Eröffnung einer neuen Laboranlage in Houston, Texas, bekannt gegeben, was eine bedeutende Erweiterung seiner Forschungsfähigkeiten im Bereich der fibroblast-basierten Therapeutika darstellt. Die neue Einrichtung umfasst über 10.000 Quadratfuß Labor- und Bürofläche und wurde entwickelt, um die Entwicklung von Behandlungen für chronische Krankheiten zu beschleunigen.
Die Erweiterung wird es dem Unternehmen ermöglichen:
- Die Entdeckungsrate potenzieller Therapeutika zu erhöhen
- Die Entwicklung von Behandlungskandidaten zu verbessern
- Potenziell die GMP-Herstellung für Arzneimittelprodukte intern zu übernehmen
- Zusätzliche Forscher einzustellen
Das Unternehmen, das über 240 Patente verfügt, die erteilt und anhängig sind, zielt darauf ab, seine Lieferkette zu optimieren und die Abhängigkeit von externen Partnern durch diese Erweiterung zu reduzieren. Die Einrichtung wird eine breitere Pipeline-Erforschung und effektivere Zusammenarbeit bei der Entwicklung fibroblast-basierter Technologien ermöglichen.
- Significant expansion with 10,000+ sq ft facility enabling increased research capacity
- Potential for in-house GMP manufacturing to reduce costs and external dependencies
- Strong intellectual property portfolio with 240+ patents issued and pending
- Planned expansion of research team to accelerate development
- Increased operational costs expected from facility expansion and new hires
- Uncertainty in timeline for achieving in-house manufacturing capabilities
- Liquidity risks highlighted in forward-looking statements
Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology
HOUSTON, April 08, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”) , a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the opening of a new laboratory facility that will expand the company’s ability to pioneer additional candidates for chronic disease-focused indications leveraging its novel fibroblast-based technology.
The new laboratory space will increase the company’s pace of discovery for potential therapeutics including multiple chronic disease indications and will enhance the development of treatment candidates for upcoming target indications. The company plans to hire additional researchers to help staff the facility and join FibroBiologics’ mission to combat chronic diseases using its fibroblast-based technology platform. The facility encompasses over 10,000-square-feet of lab and office space, with the potential of bringing in-house our GMP manufacturing for our drug product candidates we plan to use in our future clinical trials.
“This expansion marks a transformative step forward for our company and our mission,” said Pete O’Heeron, CEO and Founder of FibroBiologics. “By significantly increasing the size of our lab, we are creating the space and infrastructure needed to foster greater innovation and accelerate scientific breakthroughs. This new facility will allow our teams to explore a broader pipeline of candidates, collaborate more effectively, and push the boundaries of what is possible in treating chronic diseases. With this added capacity, we are not only scaling up our research efforts but also paving the way for in-house manufacturing of our cell therapy products. Having full control of the manufacturing process will help us streamline the supply chain and reduce our reliance on external partners. Most importantly, this investment in growth and innovation strengthens our ability to deliver life-changing therapies to patients faster and more efficiently than ever before.”
Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics added, “To date, our progress in developing potentially transformative therapeutic candidates for chronic diseases using fibroblasts has been remarkable. This new laboratory facility will enable further expansion and acceleration of our research and development efforts. Additionally, the expansive new space will enable us to bring in-house currently outsourced projects, expand our science team and further contribute to the increased efficiency of our R&D efforts.”
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning increasing research and development efforts, manufacturing drug product candidates, and hiring. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 240+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What is the size of FibroBiologics' (FBLG) new Houston laboratory facility?
How many patents does FibroBiologics (FBLG) currently have for fibroblast-based therapeutics?
What are the main benefits of FBLG's new laboratory expansion?
How will the new facility impact FBLG's manufacturing capabilities?
